Table 3.
Neonatal characteristics of infants born to treated and untreated mothers
| Apheresis Group (n=12)a | Control Group 1 (n=22) | Control Group 2 (n=22) | ||||
|---|---|---|---|---|---|---|
| Mean±SD | (Min–Max) | Mean±SD | (Min–Max) | Mean±SD | (Min–Max) | |
| Data collected at birth | ||||||
| Gestational age (weeks) | 30±2 | (26–32) | 30±2 | (25–32) | 30±2 | (25–33) |
| Birthweight (g) | 1183±306 | (580–1630) | 1204±328 | (600–1800) | 1300±381 | (530–1970) |
| Length (cm) | 39±3 | (31–44) | 39±3 | (31–43) | 39±5 | (25–46) |
| Head circumference (cm) | 27±2 | (24–29) | 28±3 | (22–34) | 28±3 | (22–32) |
| Cord blood pH | 7.28±0.08 | (7.12–7.41) | 7.29±0.06 | (7.15–7.40) | 7.33±0.08 | (7.16–7.47) |
| Apgar (5-min) | 8±1 | (7–9) | 8±1 | (5–9) | 8±1 | (5–9) |
| Apgar (10-min) | 9±1 | (7–9) | 9±1 | (7–9) | 8±1 | (8–9) |
| CRIB score | 3±2 | (1–8) | 2±2 | (1–7) | 2±3 | (0–10) |
| Data collected during follow-up | ||||||
| NICU stay (days) | 16±14 | (2–45) | 12±11 | (1–42) | 15±21 | (1–94) |
| LOS (days) | 45±17 | (27–90) | 45±15 | (21–77) | 50±23 | (14–118) |
| Ventilation (days) | 1±1 | (1–2) | 5±5 | (1–14) | 2±1 | (1–4) |
| Treated (%) | 3 (25) | 6 (27) | 6 (27) | |||
| nCPAP (days) | 6±5 | (2–17) | 13±13 | (1–56) | 9±11 | (1–48) |
| Treated (%) | 12 (100) | 22 (100) | 22 (100) | |||
| O2 (days)b | 2±2 | (1–7) | 11±15 | (1–58) | 7±13 | (1–49) |
| Treated (%) | 9 (75) | 15 (68) | 12 (55) | |||
| Surfactant (doses) | 1±0 | (1–1) | 1±1 | (1–2) | 1±1 | (1–2) |
| Treated (%) | 6 (50) | 9 (41) | 10 (45) | |||
Apheresis Group: Preterm infants of mothers with preeclampsia treated with apheresis; Control Group 1: Preterm infants of mothers with preeclampsia but not treated with apheresis; Control Group 2: Infants of mothers with preterm delivery due to other causes.
NICU, neonatal intensive care unit; LOS, total length of hospital stay; Ventilation, duration of mechanical ventilation; nCPAP, duration of nasal continuous positive airway pressure; O2, duration of oxygen supplementation.
a
One mother delivered twins, hence, 12 infants born to 11 treated mothers.
b
P<0.05 for comparison between Apheresis Group and Control Group 1; all other comparisons were not significant (P>0.05).